Drug testing for methamphetamine

Methamphetamine pharmacology and what testing detects

Methamphetamine is a synthetic phenethylamine stimulant that exists as two stereoisomers — d-methamphetamine (dextro, the abused form) and l-methamphetamine (levo, present in OTC nasal decongestants). Both isomers are detected by standard methamphetamine immunoassays, which cannot distinguish between them. Distinguishing the two requires a chiral confirmation step, and that distinction is the centerpiece of any defensible methamphetamine testing program.

Following exposure, methamphetamine is partially metabolized to amphetamine. Urinary excretion includes both parent methamphetamine and the amphetamine metabolite, with peak concentrations occurring within hours and detectable concentrations persisting roughly 1–4 days for occasional use and up to 7 days for chronic high-dose use. Detection in oral fluid extends 1–3 days. Hair testing extends the lookback to roughly 90 days for a standard 1.5-inch sample.

Routes of exposure influence pharmacokinetics — smoked, insufflated, and intravenous use produce rapid plasma peaks, while oral ingestion produces a slower rise and a longer terminal tail. Renal function, urinary pH, and dose all affect the duration of urinary positivity. As with most analytes, the published "detection window" is a clinical range, not a fixed number.

SAMHSA cutoffs and the federal confirmation rule

The SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs set the initial immunoassay screening cutoff for amphetamines (which includes methamphetamine, amphetamine, and MDMA-class compounds) at 500 ng/mL in urine. A presumptive positive at screen is reflexed to a confirmatory test by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS) at a 250 ng/mL confirmation cutoff. The same cutoff applies in 49 CFR Part 40 testing for DOT-regulated employees.

A federally regulated methamphetamine positive requires more than methamphetamine alone at 250 ng/mL. SAMHSA additionally requires detectable amphetamine at ≥100 ng/mL in the same specimen to confirm methamphetamine — a rule designed to exclude positives that could be explained by direct ingestion of certain methamphetamine-precursor or methamphetamine-metabolizing prescription medications. Confirmation laboratories produce a quantitative result for both analytes and report them together.

Specimen matrices and collection logistics for methamphetamine

Urine is the dominant matrix for methamphetamine testing because metabolite concentrations build into a defensible quantitative range over hours to days and remain detectable through the elimination tail. SAMHSA regulated collections follow the standard chain-of-custody protocol — donor identification, secured collection area with no accessible water source, bluing agent in the toilet bowl, temperature-strip reading within four minutes of void (90–100°F), and Federal Custody and Control Form documentation. Unobserved collection is the default; observed collection is reserved for return-to-duty, follow-up testing, prior dilute or invalid specimens, and contemporaneous behavioral triggers documented by the collector.

Oral fluid is increasingly used for reasonable-suspicion and post-accident testing because of its narrower recent-use window and inherently observed collection. SAMHSA oral-fluid Mandatory Guidelines authorize methamphetamine on the federal oral-fluid panel at validated cutoffs. Parent methamphetamine is the primary analyte; amphetamine appears as a metabolite. The oral-fluid window of roughly 24–72 hours for methamphetamine correlates more tightly with recent exposure than urinary detection of up to a week — a useful property when the analytical question is impairment-adjacent rather than retrospective.

Hair testing extends the lookback to roughly 90 days for a standard 1.5-inch scalp sample. Methamphetamine is a basic drug and binds melanin in the keratin matrix; hair-color bias has been documented in the toxicology literature, with darker hair concentrating basic analytes more efficiently than lighter hair at equivalent dose. Pre-analytical wash protocols address external-contamination concerns, and laboratories report parent methamphetamine alongside the amphetamine metabolite to support an active-use interpretation. Hair testing is not currently a SAMHSA-authorized matrix for federal workplace programs but is widely used in pre-employment, child-welfare, and forensic settings.

Urine pH affects methamphetamine excretion in a way that matters for chronic-use programs. Methamphetamine is a weak base; acidic urine increases the fraction excreted unchanged and shortens the apparent detection window, while alkaline urine slows renal clearance and extends it. This is a known pharmacokinetic property of the molecule and is one reason confirmation quantitative values can vary substantially across collections from the same donor at otherwise identical exposures. Specimen-validity pH testing identifies out-of-range specimens (federal cutoffs flag pH below 4.5 or above 9.0) regardless of cause.

Chiral confirmation — d-methamphetamine vs l-methamphetamine

Because illicit methamphetamine is almost exclusively d-methamphetamine while several legal products contain l-methamphetamine, chiral isomer analysis is the procedural safeguard that protects donors with legitimate OTC or prescription exposure. The Vicks Vapor Inhaler — sold over the counter in the United States — contains l-methamphetamine (l-desoxyephedrine) as its active ingredient, and heavy or recent use can produce a confirmed-positive immunoassay result.

Selegiline, prescribed for Parkinson's disease and certain depressive disorders, is metabolized to l-methamphetamine and l-amphetamine. Patients on therapeutic doses routinely produce positives on standard amphetamine immunoassays. Without chiral analysis, a selegiline-treated patient is indistinguishable from an illicit methamphetamine user at the immunoassay step.

Chiral confirmation by LC-MS/MS or GC/MS with a chiral derivatization step separates the d- and l-isomers and reports the percentage of each. Federal Medical Review Officer guidance treats a confirmed methamphetamine positive as inconsistent with l-methamphetamine-only OTC exposure when the d-isomer exceeds a defined threshold — historically 80% d-content of total methamphetamine — though programs and laboratories should confirm current MRO-handbook thresholds for their reference period.

Cross-reactivity and the pseudoephedrine question

Immunoassay manufacturers report low but measurable cross-reactivity with several sympathomimetic compounds. Pseudoephedrine and ephedrine — the active ingredients in many OTC cold medications — rarely cross-react at the 500 ng/mL federal cutoff, but cross-reactivity has been documented in some assay platforms at high donor doses. Most authoritative MRO reviews now treat pseudoephedrine cross-reactivity as uncommon in modern assays; the principal legitimate explanations for a confirmed positive remain selegiline, Vicks-inhaler use, and prescription methamphetamine.

Prescription amphetamine — Adderall (mixed amphetamine salts), Vyvanse (lisdexamfetamine), and other ADHD stimulants — produces confirmed amphetamine positives but not methamphetamine. A donor with a verified Adderall prescription should produce an amphetamine-only confirmation, not the combined methamphetamine plus amphetamine pattern that SAMHSA requires for a methamphetamine positive. The MRO process distinguishes these cases.

Bupropion (Wellbutrin) and trazodone have produced occasional historical false-positive amphetamine immunoassay results in specific platforms; modern assays generally do not cross-react, but laboratories and MROs should know the cross-reactivity profile of the specific immunoassay device in use. Point-of-care CLIA-waived devices have manufacturer cross-reactivity tables that should be reviewed against the donor populations a program serves.

Adulteration risk is non-trivial in any unobserved methamphetamine collection. Documented adulterants include household oxidants (bleach, hydrogen peroxide), nitrites, glutaraldehyde, and commercial preparations designed to interfere with immunoassay binding or to mask analyte concentrations. Specimen-validity testing addresses these threats by measuring creatinine (federal flag: dilute below 20 mg/dL, substituted below 2 mg/dL), specific gravity (cross-checked against creatinine), urinary pH (in-range 4.5–9.0), and oxidants/nitrites that signal adulterant chemicals. Specimens flagged as dilute, substituted, adulterated, or invalid are reported separately under SAMHSA and DOT rules and frequently trigger recollection under direct observation per 49 CFR Part 40 Subpart F.

The immunoassay-to-confirmation analytical gap is essential to program defensibility. The screening immunoassay produces a presumptive positive based on antibody binding above a concentration threshold; it cannot identify the specific compound responsible. GC/MS and LC-MS/MS confirmation isolate the analyte by molecular mass and characteristic fragmentation pattern, producing a defensible quantitative result for a specific molecule. Programs that report results at the screening stage — without confirmation — operate outside SAMHSA standards and expose themselves to challenge in any adverse-action proceeding. The cost of confirmation per presumptive positive is modest relative to the legal exposure of acting on an unconfirmed screen.

MRO workflow for a confirmed methamphetamine positive

Every confirmed laboratory positive in a regulated program is reviewed by a Medical Review Officer (MRO) — a licensed physician with substance-abuse-testing training — before being reported to the employer. The MRO contacts the donor, reviews any legitimate medical explanation (current prescriptions, documented OTC exposure), evaluates the quantitative laboratory values, and orders additional testing as needed. Only after this review is a verified result released to the employer.

For methamphetamine specifically, the MRO workflow typically begins with the laboratory's quantitative report of methamphetamine and amphetamine. The MRO asks the donor about current prescription medications, OTC products, and recent medical procedures. If selegiline, Vicks inhaler, or prescription methamphetamine is identified, the MRO requests chiral isomer analysis on the same specimen. The chiral result distinguishes illicit d-methamphetamine exposure from legitimate l-isomer exposure.

If no legitimate medical explanation accounts for a confirmed d-methamphetamine result, the MRO verifies the result as positive and reports it to the employer. If a legitimate explanation accounts for it — chiral analysis dominated by l-isomer in a Vicks-inhaler user, for example — the MRO reports the result as negative with appropriate documentation. The MRO process is the procedural safeguard that prevents employment action on positives explained by lawful exposure.

Program design for high-prevalence populations

Methamphetamine prevalence varies dramatically by region, occupation, and population served. NIDA and CDC surveillance data document elevated stimulant-overdose mortality across much of the western, midwestern, and southern United States, with methamphetamine-involved deaths often co-occurring with synthetic-opioid (fentanyl) involvement. Programs serving corrections populations, medication-assisted treatment (MAT) programs, and outpatient substance-use treatment in high-prevalence regions should plan for substantially elevated baseline positivity compared with general workplace populations.

For MAT programs prescribing buprenorphine or methadone, methamphetamine concurrent-use testing is standard clinical practice. Concurrent stimulant use during opioid agonist treatment is associated with worse retention and elevated overdose risk; clinicians use periodic methamphetamine testing to identify patients who would benefit from additional behavioral interventions and contingency-management protocols. Testing in this setting is therapeutic, not punitive — and clinical guidance from SAMHSA explicitly directs MAT programs to treat continued substance use as an indication for treatment intensification, not discharge.

For correctional and probation-mandated populations, frequent randomized testing is the standard. Programs should use SAMHSA cutoffs (500/250) consistently, route confirmed positives through MRO review, and obtain chiral analysis on disputed cases. Many high-prevalence programs operate panels that include both methamphetamine and fentanyl because of the documented co-prevalence of stimulant and synthetic-opioid use in these populations.

For workplace pre-employment, random, and reasonable-suspicion programs, the SAMHSA-5 panel includes amphetamines and therefore covers methamphetamine. Programs operating in high-prevalence regions or in safety-sensitive industries should consider expanded panels (12-, 14-, 17-panel devices) that add fentanyl, buprenorphine, methadone, and additional opioid analytes — the combinations now most commonly encountered in donor populations.